Thermo Fisher Scientific TNFRSF8 Monoclonal Antibody (OTI18D3), TrueMAB

Applications and Tested Dilutions

Product Specifications

Target Information

CD30 (Ki-1, TNF Receptor Superfamily Member 8) is a type I transmembrane glycoprotein of the TNF receptor superfamily. It was originally identified as a cell surface antigen of Hodgkin's and Reed-Sternberg cells using monoclonal antibody Ki-1.
The ligand for CD30 is CD30L (CD153), and their interaction mediates diverse effects such as cell proliferation, activation, differentiation, and apoptosis.
CD30 plays a critical role in the pathophysiology of Hodgkin’s disease and other CD30+ lymphomas, acting as a costimulatory molecule in thymic negative selection.
It is expressed on Hodgkin's and Reed-Sternberg cells, some non-Hodgkin’s lymphomas (including Burkitt’s), virus-infected T and B cells, and activated normal T and B cells.
In T cells, CD30 expression is associated with Th2-type cytokine production and is found on CD4+/CD8+ thymocytes co-expressing CD45RO and IL4 receptor.
Soluble CD30 (sCD30) serves as a marker for Th2 immune response. TRAF2 and TRAF5 interact with CD30, mediating NF-kappaB activation.
CD30 positively regulates apoptosis and limits the proliferative potential of autoreactive CD8 effector T cells, protecting against autoimmunity.
Two alternatively spliced transcript variants encoding distinct isoforms have been reported. CD30 is expressed by mononuclear cells in Hodgkin’s lymphoma, Reed-Sternberg cells, and most Anaplastic Large Cell Lymphomas (ALCL), as well as by embryonal carcinomas.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.